Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (March 2022)

26 slides from Sernova Biotherapeutics's investor presentation, March 2022

  1. Slide 1: Corporate Investor Deck

    Slide 1: Corporate Investor Deck

    Corporate Investor Deck March, 2022

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward- looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expect

  3. Slide 3: Sernova Corp. is a Regenerative Medicine clinical-stage company

    Slide 3: Sernova Corp. is a Regenerative Medicine clinical-stage company

    Sernova Corp. is a Regenerative Medicine clinical- stage company developing therapeutic products for chronic debilitating diseases. The Company’s proprietary Cell Pouch System™ consists of an implantable device containing immuno- protected therapeutic cells capable of sustainably producing missing t

  4. Slide 4: Investment Highlights – Cell Pouch System

    Slide 4: Investment Highlights – Cell Pouch System

    Investment Highlights – Cell Pouch System • Proprietary implantable device containing therapeutic cells for organ-like environment Proprietary Cell • Once implanted, is naturally vascularized allowing self-sustaining cell survival for years Pouch System™ • 2nd generation allows for immuno-protection

  5. Slide 5: Platform Approach: Finding Functional Cure for Chronic Diseases

    Slide 5: Platform Approach: Finding Functional Cure for Chronic Diseases

    Platform Approach: Finding Functional Cure for Chronic Diseases Integrated Regenerative Medicine Solution for Treatment of Chronic Diseases Immune Cell Pouch Protection Proprietary implantable Cell Pouch Immune 2nd generation devices utilize medical device that provides vascularized environment for

  6. Slide 6: Cell Pouch Containing Therapeutic Cells

    Slide 6: Cell Pouch Containing Therapeutic Cells

    Cell Pouch Containing Therapeutic Cells Biologically compatible delivery process – allows natural vascularization Proprietary Cell Pouch is placed Therapeutics cells are transplanted Therapeutic cells are responsive to deep under the skin, allowing for directly into the vascularized tissue endogenou

  7. Slide 7: Cell Pouch has Overcome Limitations of Previous Attempts

    Slide 7: Cell Pouch has Overcome Limitations of Previous Attempts

    Cell Pouch has Overcome Limitations of Previous Attempts Sernova has created an organ-like environment with the goal of providing ‘functional cure’ Human donor cells Tissue Vascularizes Stem cell-derived islet cells No Fibrosis Sernova Scalable Cell Pouch Natural cell environment Biocompatible Cell

  8. Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications

    Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications

    Pipeline – Life Cycle Iterations and Multiple Indications Therapeutic Immune Market Approval Product Candidate Cell Source Protection Indication Pre-Clinical Phase 1/2 Phase 3 Application Human donor islet Cell Pouch System Immunosuppressives cells Human donor islet Local immune 2nd Gen System Type

  9. Slide 9: Diabetes: Global Disease = Global Market

    Slide 9: Diabetes: Global Disease = Global Market

    GLOBAL DISEASE = GLOBAL MARKET DIABETES Diabetes is one of the module prevalent diseases pervasive medical problems, impacting society and everyday quality of life today. 537 million people are affected worldwide with Diabetes; another estimated 179 million people have it without knowing it. By 2045

  10. Slide 10: Lead Diabetes Indication: Hypoglycemia Unawareness

    Slide 10: Lead Diabetes Indication: Hypoglycemia Unawareness

    LEAD DIABETES INDICATION Hypoglycemia Unawareness Among Type 1 Diabetic Patients Hypoglycemia Unawareness – most critical unmet need in T1D Affects 15% of T1D patients (~240k patients in the US) Clinically defined as a person’s inability to recognize the symptoms of low blood sugar before they becom

  11. Slide 11: Phase 1/2 Study Design

    Slide 11: Phase 1/2 Study Design

    Phase 1/2 Study Design 7 Patients with Type 1 Diabetes (T1D) Study Overview  Company sponsored open label single-arm, single-center study Study  Enroll 7 insulin dependent T1D patients with Hypoglycemia Unawareness  Cell Pouch implant followed by human donor islets transplant to Cell Pouch Design

  12. Slide 12: Phase 1/2 Study Design

    Slide 12: Phase 1/2 Study Design

    Phase 1/2 Study Design (N = 7) Primary Study Long-term Follow-up and Tracking Baseline 1 MO +1 MO +6-12 MO +6-12 MO Ongoing Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 12

  13. Slide 13: Case Study: Longest Patient Insulin Independent for >22 Months

    Slide 13: Case Study: Longest Patient Insulin Independent for >22 Months

    Case Study: Longest Patient Insulin Independent for >22 Months Dr. Witkowski presents patient data at international conferences BEFORE ISLET TRANSPLANT Post ISLET TRANSPLANT* Post TOP-UP INFUSION** (baseline) (32 months after baseline) *Marginal Islet Dose **Marginal Islet Dose intraportal top up 83

  14. Slide 14: Sentinel Cell Pouch Histology Results - 90 Days Post-TX

    Slide 14: Sentinel Cell Pouch Histology Results - 90 Days Post-TX

    Sentinel Cell Pouch Histology Results - 90 Days Post-TX Sentinel Cell Pouch Sentinel Cell Pouch vWF+ DAPI Insulin + vWF + DAPI Insulin + vWF + DAPI Insulin +Somatostatin+ DAPI f f e e d 4x 20x d 4x 10x c c b b a a Insulin + Glucagon + DAPI Insulin +Somatostatin+ DAPI C-peptide + DAPI Insulin + CK-19

  15. Slide 15: Patient #1 – Impact Statement

    Slide 15: Patient #1 – Impact Statement

    Patient #1 – Impact Statement After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how to manage my diabetes.

  16. Slide 16: Summary of First Two Transplanted Patients in Phase 1/2 Trial

    Slide 16: Summary of First Two Transplanted Patients in Phase 1/2 Trial

    Summary of First Two Transplanted Patients in Phase 1/2 Clinical Trial (Protocol PROSVA201701) Daily CGM Severe Hypoglycemic C-Peptide HbA1c (%) Insulin Use Time in Range Events (ng/ml) PT ∆ From Baseline Post-Tx Baseline Post-Tx Baseline Post-Tx Baseline Post-Tx Baseline ↓ A 6.5 5.4 88.9% 99.6% Fre

  17. Slide 17: T1D Phase 1/2 Findings Presented To-Date

    Slide 17: T1D Phase 1/2 Findings Presented To-Date

    T1D Phase 1/2 Findings Presented To-Date The Sernova Cell Pouch System is the first regenerative medicine to demonstrate a subcutaneous transplanted device to achieve persistent islet cell graft function in T1D patients Safety Assessments1: • 6 patients now successfully implanted and transplanted wi

  18. Slide 18: Cell Pouch Diabetes Program – Progress & Upcoming Events

    Slide 18: Cell Pouch Diabetes Program – Progress & Upcoming Events

    Cell Pouch Diabetes Program – Progress & Upcoming Events Internal and External Advancement of Development and Commercialization Strategy Current Phase 1/2 Clinical Study • Completion of study enrollment; completion of patient follow-up and study report • Additional top-line data expected in 2022 Exp

  19. Slide 19: Conformal Coating Technology for Cell Pouch Immune Protection

    Slide 19: Conformal Coating Technology for Cell Pouch Immune Protection

    Conformal Coating Technology for Cell Pouch Immune Protection Potential to eliminate the need for immunosuppressives Conformal Coating University of Miami / Sernova Collaboration Plan Conformal Coating Technology developed and optimized with >12 years of research Polymer characterization studies at

  20. Slide 20: Conformal Coating + Cell Pouch: Summary of Key Findings

    Slide 20: Conformal Coating + Cell Pouch: Summary of Key Findings

    Conformal Coating + Cell Pouch: Summary of Key Findings Conformal Cell Pouch + Coating with Cells Immuno-protection Summary Cells Safety in non-human primates   • Due to its ‘shrink wrap’ proximity to the cells, the volume of cells for transplantation into the Cell Pouch is unaffected Efficacy wit

  21. Slide 21: Gene Editing for Stem Cells in Cell Pouch - Immune Protection

    Slide 21: Gene Editing for Stem Cells in Cell Pouch - Immune Protection

    Gene Editing for Stem Cells in Cell Pouch - Immune Protection AgeX technology for potential off-the-shelf islet cell transplantation product • AgeX collaboration ongoing to confirm the potential of Sernova’s pluripotent stem cell-derived pancreatic islet beta cells engineered with AgeX’s UniverCyte

  22. Slide 22: Cell Pouch System Thyroid Program

    Slide 22: Cell Pouch System Thyroid Program

    Cell Pouch System Thyroid Program Therapeutic Benefits & Estimated Market ➡ 150,000 thyroidectomies performed annually just in the US Estimated $ ➡ $2.2B market opportunity Market Size ➡ Potential near term revenue with patient own tissue ➡ Stem cell-derived technology for treatment of broad populat

  23. Slide 23: Cell Pouch System Rare Disease Program

    Slide 23: Cell Pouch System Rare Disease Program

    Cell Pouch System Rare Disease Program Hemophilia A Therapeutic Benefits & Estimated Market Estimated ➡ 20,000 patients across North America and EU Market Size $ ➡ $10B orphan indication ➡ First generation • AUTOGRAFT: Patient’s own blood outgrowth endothelial cells (BOEC) are isolated, expanded and

  24. Slide 24: Hemophilia A Indication

    Slide 24: Hemophilia A Indication

    Hemophilia A Indication Preclinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Confirmed Release-tested HLA-ABC BOECs FVIII DAPI Human stained (red) 40x Cell Pouch Transplanted with Cells Human corrected Human factor VIII- BOECs transplanted corrected blood 40× into the Cell Pouc

  25. Slide 25: Sernova Share Information

    Slide 25: Sernova Share Information

    Sernova Share Information TSX VENTURE OTC QB FRANKFURT EXCHANGE EXCHANGE XETRA SVA SEOVF PSH $1.62 US$1.27 €1.14 Shares Market Cap $420M Fully Outstanding Diluted Strong Cash ~335M ~262M Position $27M In millions except share price Share Prices and Market Cap as of February 2, 2022

  26. Slide 26: Head Office, Business Development, Investor Relations

    Slide 26: Head Office, Business Development, Investor Relations

    Head Office 700 Collip Circle, Ste 114 London, ON, Canada N6G 4X8 Tel: 1.877.299.4603 Tel: 1.519.858.5184 Fax: 1.519.858.5099 investor.relations@sernova.com Business Development Investor Relations Dr. Philip Toleikis Christopher Barnes 1.519.858.5184 VP, Investor Relations philip.toleikis@sernova.co

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks